Clinical analysis of oxaliplatin combined with capecitabine in adjuvant treatment of gastric cancer
奥沙利铂联合卡培他滨辅助治疗胃癌临床分析

摘要

目的 分析在治疗胃癌患者中应用奥沙利铂联合卡培他滨辅助治疗的应用效果。方法 选择我院于2019.10-2021.10月，2年内收治的92例胃癌患者，将所有患者随机分组为对照组（46例，采用顺铂联合氟尿嘧啶化疗）和研究组（46例，实施奥沙利铂以及卡培他滨辅助化疗）。结果 研究组治疗效果、生存质量、卡氏评分均与对照组相比较高，对照组患者不良反应发生率相比于研究组较高（P＜0.05）。结论 奥沙利铂加上卡培他滨辅助治疗胃癌可取得明显更佳的临床治疗效果，可以显著降低患者不良反应发生率，有利于生存质量的改善，有较高应用价值。

Abstract

Objectives: To analyze the effect of oxaliplatin combined with capecitabine as adjuvant therapy in patients with gastric cancer.
Methods: A total of 92 patients with gastric cancer admitted to our hospital within 2 years from October, 2019 to October, 2019 were selected. All patients were randomly divided into control group (46 cases, treated with cisplatin combined with fluorouracil chemotherapy) and study group (46 cases, Oxaliplatin and capecitabine were administered as adjuvant chemotherapy).
Results: The treatment effect, quality of life and Carver score of the study group were higher than those of the control group, and the incidence of adverse reactions of the control group was higher than that of the study group (P < 0.05).
Conclusion  : Oxaliplatin plus capecitabine can achieve significantly better clinical effect in the adjuvant treatment of gastric cancer, can significantly reduce the incidence of adverse reactions, it is conducive to the improvement of the quality of life, and has high application value.